Autophagy in Anti-tumor Immunity

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 2296

Special Issue Editors


E-Mail Website
Guest Editor
Department of Molecular and Cell Biology, Baylor College of Medicine, 120D, Jewish Building, Houston, TX 77030, USA
Interests: metabolomics; mass spectrometry; smoke and cancer

E-Mail Website
Guest Editor
Centre de Recherche des Cordeliers, Paris, France
Interests: autophagy; cancers; immunity; energetic metabolism

Special Issue Information

Dear Colleagues,

Since the discovery of this process in the middle part of the 20th century, autophagy has been shown to impact many physiological pathways and diseases. In the majority of cancers, autophagy plays a critical role in the tumor cells behavior, favoring cell survival, proliferation, migration and resistance to anti-tumor therapies. Over the time, it has become clear that the impact of autophagy is not restricted to malignant cells but can be expanded to the tumor microenvironment. Indeed, many reports described an important part for autophagy in the anti-tumor immune response, impacting immune cell survival, proliferation, differentiation as well as the expression and/or secretion of immune-related proteins.

In this special Issue of Cells, we invite contributors of original research articles, reviews, or shorter perspective paper on all aspects related to the theme of “autophagy and anti-tumor immunity”. Expert articles describing mechanistic, functional, cellular or general aspects of the role of autophagy in immune cells, immune response or in immunotherapy are highly welcome.

Dr. Nagireddy Putluri
Dr. Pierre-Emmanuel Joubert
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 5860 KiB  
Article
Normalization of the ATP1A1 Signalosome Rescinds Epigenetic Modifications and Induces Cell Autophagy in Hepatocellular Carcinoma
by Pradeep Kumar Rajan, Utibe-Abasi S. Udoh, Yuto Nakafuku, Sandrine V. Pierre and Juan Sanabria
Cells 2023, 12(19), 2367; https://doi.org/10.3390/cells12192367 - 27 Sep 2023
Viewed by 1985
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. In metabolic dysfunction-associated steatohepatitis (MASH)-related HCC, cellular redox imbalance from metabolic disturbances leads to dysregulation of the α1-subunit of the Na/K-ATPase (ATP1A1) signalosome. We have recently reported that the normalization of [...] Read more.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. In metabolic dysfunction-associated steatohepatitis (MASH)-related HCC, cellular redox imbalance from metabolic disturbances leads to dysregulation of the α1-subunit of the Na/K-ATPase (ATP1A1) signalosome. We have recently reported that the normalization of this pathway exhibited tumor suppressor activity in MASH-HCC. We hypothesized that dysregulated signaling from the ATP1A1, mediated by cellular metabolic stress, promotes aberrant epigenetic modifications including abnormal post-translational histone modifications and dysfunctional autophagic activity, leading to HCC development and progression. Increased H3K9 acetylation (H3K9ac) and H3K9 tri-methylation (H3K9me3) were observed in human HCC cell lines, HCC-xenograft and MASH-HCC mouse models, and epigenetic changes were associated with decreased cell autophagy in HCC cell lines. Inhibition of the pro-autophagic transcription factor FoxO1 was associated with elevated protein carbonylation and decreased levels of reduced glutathione (GSH). In contrast, normalization of the ATP1A1 signaling significantly decreased H3K9ac and H3K9me3, in vitro and in vivo, with concomitant nuclear localization of FoxO1, heightening cell autophagy and cancer-cell apoptotic activities in treated HCC cell lines. Our results showed the critical role of the ATP1A1 signalosome in HCC development and progression through epigenetic modifications and impaired cell autophagy activity, highlighting the importance of the ATP1A1 pathway as a potential therapeutic target for HCC. Full article
(This article belongs to the Special Issue Autophagy in Anti-tumor Immunity)
Show Figures

Figure 1

Back to TopTop